Dravet syndrome

Dravet syndrome, previously known as severe myoclonic epilepsy of infancy (SMEI), is a rare form of epilepsy usually presenting in the first 1-2 years of life.

The typical presentation occurs during the first six months to one year of life as tonic-clonic seizures in a febrile child, almost indistinguishable from febrile seizures. These progress to myoclonic seizures at age 4-5 years and are drug resistant 4

Dravet syndrome is caused by a mutation in the neuronal sodium channel gene, SCN1A. However the mutated SCN1A gene is absent in about 20% of the patients who fulfill all the diagnostic criteria of the syndrome. Therefore it is possible that genes other than SCN1A such as the GABAA-receptor gamma 2 subunit gene might be involved 1.

Only a small number of patients with Dravet syndrome demonstrate any abnormalities on MRI, which may include 5

Dravet syndrome is one of the most pharmacoresistant epilepsy syndromes. Valproate is used as a first-line agent to prevent the recurrence of febrile seizures and oral/nasal/rectal benzodiazepine is used for any long-lasting seizures. Stiripentol (Diacomit®) was approved as an orphan drug in 2007 in Europe for adjunctive therapy in Dravet syndrome 2. Ketogenic diet may be used as an adjunct to treatment.

It was named after French pediatric epileptologist Charlotte Dravet (1936- fl.2018) who described this condition for the first time in 1978 as severe myoclonic epilepsy 3.

Article information

rID: 30521
Section: Syndromes
Synonyms or Alternate Spellings:
  • Dravet syndrome (DS)
  • Severe myoclonic epilepsy of infancy (SMEI)

Support Radiopaedia and see fewer ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.